BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
The most effective method to Go Down Abundance through Ages with Disc Rates- Nestlé recalls infant formula in 49 countries. See list.
- The beauty advent calendar boom is here. Sephora kids are all in.
- A Concise History Of The Entertainment world
- Nutrient Rich Natural products: Lift Your Wellbeing
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- Vote In favor of Your #1 Electric Vehicles
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
